title: Increased efficacy of a dendritic cell-based therapeutic cancer vaccine with adenosine receptor antagonist and CD73 inhibitor.
abstract: Dendritic cells are important in initiating immune responses; therefore, a range of dendritic cell-based approaches have been established to induce immune response against cancer cells. However, the presence of immunosuppressive mediators such as adenosine in the tumor microenvironment reduces the efficacy of dendritic cell-based cancer immunotherapy. In this study, we investigated whether blockade of the A2A adenosine receptor with a selective antagonist and a CD73 inhibitor may increase the efficacy of a dendritic cell-based cancer vaccine. According to the findings, this therapeutic combination reduced tumor growth, prolonged survival of tumor-bearing mice, and enhanced specific antitumor immune responses. Thus, we suggest that targeting cancer-derived adenosine improves the outcomes of dendritic cell-based cancer immunotherapy.
authors.affiliation: 1 Department of Molecular Medicine, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran.
authors.forename: Samaneh
authors.initials: S
authors.lastname: Arab
authors.affiliation: 2 Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
authors.forename: Nasim
authors.initials: N
authors.lastname: Kheshtchin
authors.affiliation: 3 Department of Immunology, Tarbiat Modares University, Tehran, Iran.
authors.forename: Maryam
authors.initials: M
authors.lastname: Ajami
authors.affiliation: 4 Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
authors.forename: Mahbubeh
authors.initials: M
authors.lastname: Ashurpoor
authors.affiliation: 2 Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
authors.forename: Aida
authors.initials: A
authors.lastname: Safvati
authors.affiliation: 2 Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
authors.forename: Afshin
authors.initials: A
authors.lastname: Namdar
authors.affiliation: 2 Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
authors.forename: Reza
authors.initials: R
authors.lastname: Mirzaei
authors.affiliation: 5 Department of Biotechnology, Faculty of Advanced Medical Sciences, Tehran Medical Branch, Islamic Azad University, Tehran, Iran.
authors.forename: Neda
authors.initials: N
authors.lastname: Mousavi Niri
authors.affiliation: 4 Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.|6 Department of Immunology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.|7 Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
authors.forename: Farhad
authors.initials: F
authors.lastname: Jadidi-Niaragh
authors.affiliation: 1 Department of Molecular Medicine, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran.
authors.forename: Mohammad Hossein
authors.initials: MH
authors.lastname: Ghahremani
authors.affiliation: 2 Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
authors.forename: Jamshid
authors.initials: J
authors.lastname: Hadjati
mesh_terms: D015720:5'-Nucleotidase / Q000037:antagonists & inhibitors* / Q000276:immunology; D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000276:immunology; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D019496:Cancer Vaccines / Q000235:genetics / Q000276:immunology* / Q000627:therapeutic use; D045744:Cell Line, Tumor; D064987:Cell- and Tissue-Based Therapy; D003713:Dendritic Cells / Q000276:immunology; D005260:Female; D058851:GPI-Linked Proteins / Q000037:antagonists & inhibitors / Q000276:immunology; D006801:Humans; D007113:Immunity, Innate / Q000187:drug effects; D051379:Mice; D009374:Neoplasms, Experimental / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D058915:Purinergic P1 Receptor Antagonists / Q000008:administration & dosage*; D043705:Receptor, Adenosine A2A / Q000235:genetics / Q000276:immunology*; D059016:Tumor Microenvironment / Q000187:drug effects / Q000276:immunology
chemical_list: D000911:Antibodies, Monoclonal; D019496:Cancer Vaccines; D058851:GPI-Linked Proteins; D058915:Purinergic P1 Receptor Antagonists; D043705:Receptor, Adenosine A2A; D015720:5'-Nucleotidase; C548241:NT5E protein, human
keywords: Adenosine; CD73; cancer; dendritic cell; immunotherapy